ArriVent BioPharma (AVBP) Change in Account Payables (2023 - 2026)

ArriVent BioPharma has disclosed Change in Account Payables across 4 years of filings, most recently posting $2.8 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at $2.8 million, up 382.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.4 million (up 2029.76% YoY), and the FY2025 annual result was $2.1 million, up 385.09% from the prior year.
• Change in Account Payables came in at $2.8 million for Q1 2026 at ArriVent BioPharma, up from -$8000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $3.7 million in Q2 2023 to a low of -$2.2 million in Q3 2023.
• The 4-year median for Change in Account Payables is -$8000.0 (2025), against an average of $428923.1.
• Across the five-year window, Change in Account Payables sank 393.22% in 2024 and jumped 382.3% in 2026, its largest moves.
• ArriVent BioPharma's Change in Account Payables stood at $295000.0 in 2023, then tumbled by 393.22% to -$865000.0 in 2024, then jumped by 99.08% to -$8000.0 in 2025, then surged by 35187.5% to $2.8 million in 2026.
• The last three Change in Account Payables figures came in at $2.8 million (Q1 2026), -$8000.0 (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.